Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Amra
  IRCT20170207032444N3		 RCTthalidomide standard of careCOVID-19 severe or criticallyhigh
30/30 inconclusive
    Fakharian
          IRCT20151227025726N2    		 RCTadalimumabCOVID-19 severe or criticallysome concern
    		34/34 ongoing
      Kumar
              CTRI/2020/05/024959      		 RCTitolizumabstandard of careCOVID-19 severe or criticallyhigh
      		22/10 inconclusive
        CAN-COVID
                  NCT04362813        		 RCTcanakinumabplaceboCOVID-19 severe or criticallysome concern
        		227/227 inconclusive
        • inconclusive 39 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons